Correlation Between Conduit Pharmaceuticals and Puma Biotechnology
Can any of the company-specific risk be diversified away by investing in both Conduit Pharmaceuticals and Puma Biotechnology at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Conduit Pharmaceuticals and Puma Biotechnology into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Conduit Pharmaceuticals and Puma Biotechnology, you can compare the effects of market volatilities on Conduit Pharmaceuticals and Puma Biotechnology and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Conduit Pharmaceuticals with a short position of Puma Biotechnology. Check out your portfolio center. Please also check ongoing floating volatility patterns of Conduit Pharmaceuticals and Puma Biotechnology.
Diversification Opportunities for Conduit Pharmaceuticals and Puma Biotechnology
-0.46 | Correlation Coefficient |
Very good diversification
The 3 months correlation between Conduit and Puma is -0.46. Overlapping area represents the amount of risk that can be diversified away by holding Conduit Pharmaceuticals and Puma Biotechnology in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Puma Biotechnology and Conduit Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Conduit Pharmaceuticals are associated (or correlated) with Puma Biotechnology. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Puma Biotechnology has no effect on the direction of Conduit Pharmaceuticals i.e., Conduit Pharmaceuticals and Puma Biotechnology go up and down completely randomly.
Pair Corralation between Conduit Pharmaceuticals and Puma Biotechnology
Assuming the 90 days horizon Conduit Pharmaceuticals is expected to generate 3.68 times more return on investment than Puma Biotechnology. However, Conduit Pharmaceuticals is 3.68 times more volatile than Puma Biotechnology. It trades about 0.12 of its potential returns per unit of risk. Puma Biotechnology is currently generating about 0.04 per unit of risk. If you would invest 1.08 in Conduit Pharmaceuticals on December 4, 2024 and sell it today you would earn a total of 0.42 from holding Conduit Pharmaceuticals or generate 38.89% return on investment over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Against |
Strength | Very Weak |
Accuracy | 86.44% |
Values | Daily Returns |
Conduit Pharmaceuticals vs. Puma Biotechnology
Performance |
Timeline |
Conduit Pharmaceuticals |
Puma Biotechnology |
Conduit Pharmaceuticals and Puma Biotechnology Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Conduit Pharmaceuticals and Puma Biotechnology
The main advantage of trading using opposite Conduit Pharmaceuticals and Puma Biotechnology positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Conduit Pharmaceuticals position performs unexpectedly, Puma Biotechnology can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Puma Biotechnology will offset losses from the drop in Puma Biotechnology's long position.Conduit Pharmaceuticals vs. Hurco Companies | Conduit Pharmaceuticals vs. MYR Group | Conduit Pharmaceuticals vs. Altair Engineering | Conduit Pharmaceuticals vs. Grupo Aeroportuario del |
Puma Biotechnology vs. Ultragenyx | Puma Biotechnology vs. Crinetics Pharmaceuticals | Puma Biotechnology vs. Arvinas | Puma Biotechnology vs. Revolution Medicines |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Other Complementary Tools
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |